TY - JOUR
T1 - Rubella vaccine introduction in the South African public vaccination schedule
T2 - Mathematical modelling for decision making
AU - Motaze, Nkengafac Villyen
AU - Edoka, Ijeoma
AU - Wiysonge, Charles S.
AU - Metcalf, C. Jessica E.
AU - Winter, Amy K.
N1 - Funding Information:
Funding: This research was funded by the Oppenheimer Memorial Trust, grant number 20592 and Princeton University by providing a Visiting Student Research Scholar fellowship to NVM. The APC was funded by the National Institute for Communicable Diseases (NICD) a division of the National Health Laboratory Service (NHLS), South Africa.
Funding Information:
This research was funded by the Oppenheimer Memorial Trust, grant number 20592 and Princeton University by providing a Visiting Student Research Scholar fellowship to NVM. The APC was funded by the National Institute for Communicable Diseases (NICD) a division of the National Health Laboratory Service (NHLS), South Africa. We would like to acknowledge Melinda Suchard and other members of the National Advisory Group on Immunization (NAGI) of South Africa for their invaluable input.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9
Y1 - 2020/9
N2 - Background: age structured mathematical models have been used to evaluate the impact of rubella-containing vaccine (RCV) introduction into existing measles vaccination programs in several countries. South Africa has a well-established measles vaccination program and is considering RCV introduction. This study aimed to provide a comparison of different scenarios and their relative costs within the context of congenital rubella syndrome (CRS) reduction or elimination. Methods: we used a previously published age-structured deterministic discrete time rubella transmission model. We obtained estimates of vaccine costs from the South African medicines price registry and the World Health Organization. We simulated RCV introduction and extracted estimates of rubella incidence, CRS incidence and effective reproductive number over 30 years. Results: compared to scenarios without mass campaigns, scenarios including mass campaigns resulted in more rapid elimination of rubella and congenital rubella syndrome (CRS). Routine vaccination at 12 months of age coupled with vaccination of nine-year-old children was associated with the lowest RCV cost per CRS case averted for a similar percentage CRS reduction. Conclusion: At 80% RCV coverage, all vaccine introduction scenarios would achieve rubella and CRS elimination in South Africa. Any RCV introduction strategy should consider a combination of routine vaccination in the primary immunization series and additional vaccination of older children.
AB - Background: age structured mathematical models have been used to evaluate the impact of rubella-containing vaccine (RCV) introduction into existing measles vaccination programs in several countries. South Africa has a well-established measles vaccination program and is considering RCV introduction. This study aimed to provide a comparison of different scenarios and their relative costs within the context of congenital rubella syndrome (CRS) reduction or elimination. Methods: we used a previously published age-structured deterministic discrete time rubella transmission model. We obtained estimates of vaccine costs from the South African medicines price registry and the World Health Organization. We simulated RCV introduction and extracted estimates of rubella incidence, CRS incidence and effective reproductive number over 30 years. Results: compared to scenarios without mass campaigns, scenarios including mass campaigns resulted in more rapid elimination of rubella and congenital rubella syndrome (CRS). Routine vaccination at 12 months of age coupled with vaccination of nine-year-old children was associated with the lowest RCV cost per CRS case averted for a similar percentage CRS reduction. Conclusion: At 80% RCV coverage, all vaccine introduction scenarios would achieve rubella and CRS elimination in South Africa. Any RCV introduction strategy should consider a combination of routine vaccination in the primary immunization series and additional vaccination of older children.
KW - Age-structured rubella transmission model
KW - Congenital rubella syndrome
KW - Rubella
KW - Rubella-containing vaccine
KW - Vaccine introduction strategies
UR - http://www.scopus.com/inward/record.url?scp=85087935859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087935859&partnerID=8YFLogxK
U2 - 10.3390/vaccines8030383
DO - 10.3390/vaccines8030383
M3 - Article
C2 - 32668819
AN - SCOPUS:85087935859
SN - 2076-393X
VL - 8
SP - 1
EP - 15
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 383
ER -